1887
Volume 2025, Issue 3
  • ISSN: 0253-8253
  • EISSN: 2227-0426

Abstract

Guillain–Barré Syndrome (GBS) is a severe neurological disorder in which the immune system attacks the peripheral nervous system, leading to acute flaccid paralysis. The conventional treatment involves intravenous immunoglobulin (IVIG), yet the efficacy of a second IVIG dose remains uncertain. This systematic review aims to evaluate the clinical outcomes of administering a second dose of IVIG in GBS patients.

The review was registered in the PROSPERO database (CRD42024557465) and adhered to Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) standards. Databases including EBSCO, MEDLINE, CINAHL, and SCOPUS were searched from database inception until June 2024, using a combination of relevant keywords. Only English-language studies were included. Quality assessment was conducted using the Joanna Briggs Institute critical appraisal tools. In total, 89 abstracts were initially screened, 20 full-text articles were reviewed, and 10 studies met the inclusion criteria for final evaluation.

The review included 10 studies with 94 patients across all included studies (31 female, 63 male). This review includes two clinical trials, six case studies, and two case report series, conducted across Europe and Asia. The studies evaluated the clinical outcomes of a second IVIG dose in GBS patients in various healthcare settings, such as emergency rooms, medical departments, and intensive care units. Most of these studies reported significant clinical improvements in motor symptoms and successful weaning from mechanical ventilation following the administration of a second IVIG dose. Eighty percent of the studies included patients on mechanical ventilation, with a standard IVIG dose of 0.4 g/kg reported in 60% of studies. Half of the studies administered the second IVIG dose 2 weeks after the first. Seventy percent of the studies reported clinical motor improvement following the second IVIG dose, with half indicating successful weaning from mechanical ventilation. Evaluation methods varied, with cerebrospinal fluid protein testing (60%) and nerve conduction studies (50%) being the most common. A smaller proportion of studies assessed GMI/GDIA antibodies, immunoglobulin G (IgG) levels, or conducted electrophysiological studies. The findings demonstrate the potential effectiveness of a second IVIG dose in improving motor outcomes and reducing ventilator dependency in GBS patients.

The findings suggest that a second dose of IVIG may enhance clinical outcomes in GBS patients, particularly in improving motor functions and facilitating weaning from mechanical ventilation. However, further prospective randomized trials are essential to validate these results and improve treatment protocols.

© 2025 Alnaeem, Al-Qudimat, Talafha, Alqaisi, licensee HBKU Press.
Loading

Article metrics loading...

/content/journals/10.5339/qmj.2025.88
2025-09-25
2025-12-15

Metrics

Loading full text...

Full text loading...

/deliver/fulltext/qmj/2025/3/qmj.2025.88.html?itemId=/content/journals/10.5339/qmj.2025.88&mimeType=html&fmt=ahah

References

  1. World Health Organization: WHO . Guillain–Barré syndrome; 2016, August 17. Available from:https://iris.who.int/bitstream/handle/10665/204474/WHO_ZIKV_MOC_16.4_eng.pdf?sequence=1
     [Google Scholar]
  2. Walgaard C, Jacobs BC, Lingsma HF, Steyerberg EW, van den Berg B, Doets AY, et al. Second intravenous immunoglobulin dose in patients with Guillain–Barré syndrome with poor prognosis (SID-GBS): A double-blind, randomised, placebo-controlled trial. Lancet Neurol. 2021; 20:(4):275–83. https://doi.org/10.1016/S1474-4422(20)30494-4
     [Google Scholar]
  3. World Health Organization: WHO . Guillain–Barré syndrome; 2023 August 15. Available from:https://www.who.int/news-room/fact-sheets/detail/guillain-barr%C3%A9-syndrome#:~:text=Guillain%2DBarr%C3%A9%20syndrome%20(GBS).
     [Google Scholar]
  4. Yi S-W, Lee JH, Hong J-M, Choi Y-C, Park HJ. Incidence, disability, and mortality in patients with Guillain–Barré syndrome in Korea: A nationwide population-based study. J Clin Neurol. 2022 Jan; 18:(1):48–58. https://doi.org/10.3988/jcn.2022.18.1.48
     [Google Scholar]
  5. Chakraborty T, Kramer CL, Wijdicks EFM, Rabinstein AA. Dysautonomia in Guillain–Barré syndrome: Prevalence, clinical spectrum, and outcomes. Neurocrit Care. 2020 Feb; 32:(1):113–20. https://doi.org/10.1007/s12028-019-00781-w
     [Google Scholar]
  6. Tewedaj ZD, Huluka DK, Kebede YT, Abebe AT, Hussen MS, Mohammed BD, et al. A retrospective analysis of the clinical profile and factors associated with mortality and poor hospital outcomes in adult Guillain–Barre syndrome patients. Sci Rep. 2024 Jul 5; 14:(1):15520. https://doi.org/10.1038/s41598-024-65265-0
     [Google Scholar]
  7. Dalakas M C. Pathogenesis of immune-mediated neuropathies. Biochim Biophys Acta. 2015 Apr; 1852:(4):658–66. https://doi.org/10.1016/j.bbadis.2014.06.013
     [Google Scholar]
  8. Dalakas MC. Guillain–Barré syndrome: The first documented COVID-19-triggered autoimmune neurologic disease: More to come with myositis in the offing. Neurol Neuroimmunol Neuroinflamm. 2020 Jun 9; 7:(5):e781. https://doi.org/10.1212/NXI.0000000000000781
     [Google Scholar]
  9. Umapathi T. Does COVID-19 cause axonal GBS? J Clin Neurosci. 2020 Aug; 78:: 448. https://doi.org/10.1016/j.jocn.2020.05.057
     [Google Scholar]
  10. Finsterer J. Triggers of Guillain–Barré syndrome: Campylobacter jejuni predominates. Int J Mol Sci. 2022 Nov 17; 23:(22):14222. https://doi.org/10.3390/ijms232214222
     [Google Scholar]
  11. Huang C, Zhang Y, Deng S, Ren Y, Lu W. Trauma-related Guillain–Barré syndrome: Systematic review of an emerging concept. Front Neurol. 2020 Nov 6; 11:: 588290. https://doi.org/10.3389/fneur.2020.588290
     [Google Scholar]
  12. Shastri A, Al Aiyan A, Kishore U, Farrugia ME. Immune-mediated neuropathies: Pathophysiology and management. Int J Mol Sci. 2023 Apr 14; 24:(8):7288. https://doi.org/10.3390/ijms24087288
     [Google Scholar]
  13. Verboon C, Doets AY, Galassi G, Davidson A, Waheed W, Péréon Y, et al. Current treatment practice of Guillain–Barré syndrome. Neurology. 2019 Jul 2; 93:(1):e59–76. https://doi.org/10.1212/WNL.0000000000007719
     [Google Scholar]
  14. Campbell, M., McKenzie, J. E., Sowden, A., Katikireddi, S. V., Brennan, S. E., Ellis, S., et al. Synthesis without meta-analysis (SWiM) in systematic reviews: reporting guideline. Bmj. January 2020, 368. https://doi.org/10.1136/bmj.l6890
     [Google Scholar]
  15. Lopes M, Marques P, Silva B, Cruz G, Serra JE, Ferreira E, et al. Guillain–Barré syndrome as the first presentation of human immunodeficiency virus infection. BMC Neurol. 2021 Aug 18; 21:(1):321. https://doi.org/10.1186/s12883-021-02350-1
     [Google Scholar]
  16. Vembu P, Al-Shubaili A, Al-Khuraibet A, Kreze O, Pandita R. Guillain–Barre syndrome in a case of acute lymphoblastic leukaemia: A case report. Med Princ Pract. 2003 Oct-Dec; 12:(4):272–5. https://doi.org/10.1159/000072298
     [Google Scholar]
  17. Miyamoto, M., Imataka, G., Ichikawa, G., Saito, Y., Kashiwagi, T., Kaji, Y., … & Yoshihara, S. Successful treatment of a 12yearold boy with GuillainBarré syndrome requiring tracheostomy due to respiratory muscle paralysis: A case report. Experimental and Therapeutic Medicine. 2020; 19:(2), 1091–1094. https://doi.org/10.3892/etm.2019.8311
     [Google Scholar]
  18. Shalman A, Savir S, Steen YM, Ovanyan A, Boniel N, Koyfman L, et al. Albumin levels as a biomarker for second Intravenous Immunoglobulin (IVIG) treatment in Guillain–Barre syndrome (GBS). J Clin Neurosci. 2020 Apr; 74:: 247–9. https://doi.org/10.1016/j.jocn.2020.01.067
     [Google Scholar]
  19. Okoh HC, Lubana SS, Langevin S, Sanelli-Russo S, Abrudescu A. A case of systemic lupus erythematosus presenting as Guillain–Barré syndrome. Case Rep Rheumatol. 2015; 2015:: 528026. https://doi.org/10.1155/2015/528026
     [Google Scholar]
  20. Godoy DA, Rabinstein A. Is a second cycle of immunoglobulin justified in axonal forms of Guillain–Barré syndrome?. Arq Neuropsiquiatr. 2015 Oct; 73:(10):848–51. https://doi.org/10.1590/0004-282X20150136
     [Google Scholar]
  21. Farcas P, Avnun L, Frisher S, Herishanu YO, Wirguin I. Efficacy of repeated intravenous immunoglobulin in severe unresponsive Guillain–Barré syndrome. Lancet. 1997 Dec 13; 350:(9093):1747. https://doi.org/10.1016/s0140-6736(97)24050-x
     [Google Scholar]
  22. Verboon C, van Den Berg B, Cornblath DR, Venema E, Gorson KC, Lunn MP, et al. Second IVIg course in Guillain–Barré syndrome with poor prognosis: The non-randomised ISID study. J Neurol Neurosurg Psychiatry. 2020 Feb; 91:(2):113–21. https://doi.org/10.1136/jnnp-2019-321496
     [Google Scholar]
  23. Kinboshi M, Morimoto Y, Yoshida T, Kuzume D, Yamasaki M. An elderly case of Guillain–Barré syndrome with anti-GT1b antibodies. Rinsho Shinkeigaku. 2019 Sep 25; 59:(9):600–3. https://doi.org/10.5692/clinicalneurol.cn-001304
     [Google Scholar]
  24. Farcas, P., Avnun, L., Frisher, S., Herishanu, Y., & Wirguin, I. Efficacy of repeated intravenous immunoglobulin in severe unresponsive Guillain-Barré syndrome. 1997. The Lancet, 350:(9093), 1747. https://doi.org/10.1016/s0140-6736(97)24050-x
     [Google Scholar]
  25. Walgaard, C., Jacobs, B. C., Lingsma, H. F., Steyerberg, E. W., van den Berg, B., Doets, A. Y., et al. Second intravenous immunoglobulin dose in patients with Guillain-Barré syndrome with poor prognosis (SID-GBS): a double-blind, randomised, placebo-controlled trial. 2021. Lancet Neurol, 20:(4), 275–283. https://doi.org/10.1016/S1474-4422(20)30494-4
     [Google Scholar]
  26. Brem, M. D., Jacobs, B. C., van Rijs, W., Fokkink, W. J. R., Tio-Gillen, A. P., Walgaard , et al. IVI g-induced plasmablasts in patients with Guillain-Barré syndrome. 2019. Annals of Clinical and Translational Neurology, 6:(1), 129–143. https://doi.org/10.1002/acn3.687
     [Google Scholar]
  27. Shahrizaila, N., Lehmann, H. C., & Kuwabara, S. (2021). Guillain-barré syndrome. The lancet, 397:(10280), 1214–1228. https://doi.org/10.1016/S0140-6736(21)00517-1
     [Google Scholar]
  28. Shang P, Zhu M, Baker M, Feng J, Zhou C, Zhang HL. Mechanical ventilation in Guillain–Barré syndrome. Expert Rev Clin Immunol. 2020 Nov; 16:(11):1053–64. https://doi.org/10.1080/1744666X.2021.1840355
     [Google Scholar]
  29. Melone MA, Heming N, Meng P, Mompoint D, Aboab J, Clair B, et al. Early mechanical ventilation in patients with Guillain–Barré syndrome at high risk of respiratory failure: A randomized trial. Ann Intensive Care. 2020 Sep 30; 10:(1):128. https://doi.org/10.1186/s13613-020-00742-z
     [Google Scholar]
  30. van den Berg B, Storm EF, Garssen MJ, Blomkwist-Markens PH, Jacobs BC. Clinical outcome of Guillain–Barré syndrome after prolonged mechanical ventilation. J Neurol Neurosurg Psychiatry. 2018 Sep; 89:(9):949–54. https://doi.org/10.1136/jnnp-2018-317968
     [Google Scholar]
  31. Wu X, Li C, Zhang B, Shen D, Li T, Liu K, et al. Predictors for mechanical ventilation and short-term prognosis in patients with Guillain–Barré syndrome. Crit Care. 2015 Sep 2; 19:(1):310. https://doi.org/10.1186/s13054-015-1037-z
     [Google Scholar]
  32. Willison, H. J., Jacobs, B. C., & van Doorn, P. A. Guillain-barre syndrome. 2016. The Lancet, 388:(10045), 717–727. https://doi.org/10.1016/S0140-6736(16)00339-1
     [Google Scholar]
  33. Fokkink W JR, van Tilburg SJ, de Winter BCM, Sassen SDT, van Doorn PA, Koch BCP, et al. Population pharmacokinetic modelling of intravenous immunoglobulin treatment in patients with Guillain–Barré syndrome. Clin Pharmacokinet. 2022 Sep; 61:(9):1285–96. https://doi.org/10.1007/s40262-022-01136-z
     [Google Scholar]
  34. Lin J, Gao Q, Xiao K, Tian D, Hu W, Han Z. Efficacy of therapies in the treatment of Guillain–Barre syndrome: A network meta-analysis. Medicine (Baltimore). 2021 Oct 15; 100:(41):e27351. https://doi.org/10.1097/MD.0000000000027351
     [Google Scholar]
  35. Khan MH, Islam MK, Rahman S, Rahman AKMF, Mohsin M, Sarker SK. Effectiveness of plasmapheresis and IVIG in the treatment of Guillain–Barre syndrome: A cross-sectional observational study. Bangladesh Crit Care J. 2023 Sep; 11:(2): 95–102. Available from:https://www.banglajol.info/index.php/BCCJ/article/view/69194/46272
     [Google Scholar]
  36. Ram D, Aziz M. G99 (P) IVIG for Guillain–Barré syndrome: Which regimen should i choose? Arch Dis Child. 2016; 101:(Suppl 1). https://doi.org/10.1136/archdischild-2016-310863.96
     [Google Scholar]
  37. Verboon C, Harbo T, Cornblath DR, Hughes RAC, van Doorn PA, Lunn MP, et al. Intravenous immunoglobulin treatment for mild Guillain–Barré syndrome: An international observational study. J Neurol Neurosurg Psychiatry. 2021 Oct; 92:(10):1080–8. https://doi.org/10.1136/jnnp-2020-325815
     [Google Scholar]
  38. Shalem D, Shemer A, Shovman O, Shoenfeld Y, Kivity S. The efficacy of intravenous immunoglobulin in Guillain–Barré syndrome: The experience of a tertiary medical center. Isr Med Assoc J. 2018 Dec; 20:(12):754–60. Available from:https://pubmed.ncbi.nlm.nih.gov/30550005/
     [Google Scholar]
  39. Godoy, D. A., & Rabinstein, A. Is a second cycle of immunoglobulin justified in axonal forms of Guillain-Barré syndrome?. 2015. Arquivos de Neuro-Psiquiatria, 73:, 848–851. https://doi.org/10.1590/0004-282X20150136
     [Google Scholar]
  40. Shang P, Feng J, Wu W, Zhang HL. Intensive care and treatment of severe Guillain–Barré syndrome. Front Pharmacol. 2021 Apr 27; 12:: 608130. https://doi.org/10.3389/fphar.2021.608130
     [Google Scholar]
  41. Weiss, N. Should We Assess Diaphragmatic Function During Mechanical Ventilation Weaning in Guillain–Barré Syndrome and Myasthenia Gravis Patients?. 2021. Neurocritical Care, 34:(2), 371–374. https://doi.org/10.1007/s12028-020-01159-z
     [Google Scholar]
  42. Dugernier J, Bialais E, Reychler G, Vinetti M, Hantson P. Neurally adjusted ventilatory assist during weaning from respiratory support in a case of Guillain–Barre syndrome. Respir Care. 2015 Apr; 60:(4), e68–72. https://doi.org/10.4187/respcare.03507
     [Google Scholar]
  43. Khdair SI, Al-Khareisha L, Abusara OH, Hammad AM, Khudair A. HLA-class II genes association with multiple sclerosis: An immunogenetic prediction among multiple sclerosis Jordanian patients. PLoS One. 2025 Feb 25; 20:(2):e0318824. https://doi.org/10.1371/journal.pone.0318824
     [Google Scholar]
  44. Vlam L, Cats EA, Willemse E, Franssen H, Medic J, Piepers S, et al. Pharmacokinetics of intravenous immunoglobulin in multifocal motor neuropathy. J Neurol Neurosurg Psychiatry. 2014 Oct; 85:(10):1145–8. https://doi.org/10.1136/jnnp-2013-306227
     [Google Scholar]
  45. Zihlif, M., Abusara, O. H., Al-Qerem, W., Al-Ibadah, M., Mahafza, T. M., Al-Akhras, F. M., & Mahafza, N. T. CRHR1 polymorphism at rs242941, rs242940, and rs72834580: association of symptoms improvement with intranasal corticosteroids in allergic rhinitis Jordanian patients. 2024. Drug Metabolism and Personalized Therapy, 38:(4), 331–338. https://doi.org/10.1515/dmpt-2023-0014
     [Google Scholar]
  46. Zihlif M, Imraish A, Al-Rawashdeh B, Qteish A, Husami R, Husami R, et al. The association of IgE levels with ADAM33 genetic polymorphisms among asthmatic patients. J Pers Med. 2021 Apr 22; 11:(5):329. https://doi.org/10.3390/jpm11050329
     [Google Scholar]
  47. Kapoor M, Hunt I, Spillane J, Bonnett LJ, Hutton EJ, McFadyen J, et al. IVIg-exposure and thromboembolic event risk: Findings from the UK Biobank. J Neurol Neurosurg Psychiatry. 2022 Aug; 93:(8):876–85. https://doi.org/10.1136/jnnp-2022-328881
     [Google Scholar]
  48. van Tilburg SJ, Huizinga R, Kuitwaard K, Sassen SDT, Walgaard C, van Doorn PA, et al. If it does not help, it might hurt: Pharmacodynamics of a second IVIg course in Guillain–Barré syndrome. Ann Clin Transl Neurol. 2025 May; 12:(5):966–75. https://doi.org/10.1002/acn3.52313
     [Google Scholar]
  49. Leonhard SE, Mandarakas MR, Gondim FAA. Bateman K, Ferreira MLB, Cornblath DR, et al. Diagnosis and management of Guillain–Barré syndrome in ten steps. Nat Rev Neurol. 2019 Nov; 15:(11):671–83. https://doi.org/10.1038/s41582-019-0250-9
     [Google Scholar]
  50. Kamal MM, Habib M, Islam MR, Ghose SK, Uddin KG, Chowdhury AH, et al. Cerebrospinal fluid protein level and nerve conduction study as short-term prognostic marker of Guillain–Barré syndrome. Bangladesh J Neurosci. 2018 Jul; 34:(2):79–84. https://doi.org/10.3329/bjn.v34i2.57551
     [Google Scholar]
  51. Kılıç B, Güngör S, Özgör B. Clinical, electrophysiological findings and evaluation of prognosis of patients with Guillain–Barré syndrome. Turkish J Pediatr. 2019; 61:(2):200–8. https://doi.org/10.24953/turkjped.2019.02.008
     [Google Scholar]
  52. Syczewska M, Swiecicka A, Szczerbik E, Kalinowska M, Dunin-Wasowicz D, Łukowicz M. Types of gait deviations in children and adolescents with Guillain–Barre syndrome identified using cluster analysis. Biomed Signal Process Control. 2021 Apr; 66:: 102496 https://doi.org/10.1016/j.bspc.2021.102496
     [Google Scholar]
  53. Jawaid W, Sana R, Umer SR, Nisa Q, Butt M, Shahbaz N. Relationship between cerebrospinal fluid protein level and electrophysiologic abnormalities in the acute inflammatory demyelinating polyradiculoneuropathy variant of Guillain–Barré syndrome. Ger Med Sci. 2021 Sep 1; 19:: Doc12. https://doi.org/10.3205/000299
     [Google Scholar]
  54. Kim S, Han HJ, Shin HY, Kim S W. Old age and multiple comorbidity are associated with delayed diagnosis of Guillain–Barre syndrome. Sci Rep. 2022 Jun 15; 12:(1):9913. https://doi.org/10.1038/s41598-022-14184-z
     [Google Scholar]
  55. Chang KH, Lyu RK, Lin WT, Huang YT, Lin HS, Chang SH. Gulllain-Barre syndrome after trivalent influenza vaccination in adults. Front Neurol. 2019 Jul 24; 10:: 768. https://doi.org/10.3389/fneur.2019.00768
     [Google Scholar]
  56. Maskin LP, Wilken M, Lucci FR, Wisnivesky JP, Barroso F, Wainsztein N. Risk factors for respiratory failure among hospitalized patients with Guillain–Barré syndrome. Neurología (English Edition). 2024 Jan-Feb; 39:(1):36–42. https://doi.org/10.1016/j.nrl.2021.04.011
     [Google Scholar]
  57. Sejvar JJ, Baughman AL, Wise M, Morgan OW. Population incidence of Guillain–Barré syndrome: A systematic review and meta-analysis. Neuroepidemiology. 2011; 36:(2):123–33. https://doi.org/10.1159/000324710
     [Google Scholar]
/content/journals/10.5339/qmj.2025.88
Loading
Assessing the impact of a second IVIG dose on patients with Guillain–Barré Syndrome: A synthesis without meta-analysis (SWiM)
Qatar Medical Journal 2025, 88 (2025); https://doi.org/10.5339/qmj.2025.88
/content/journals/10.5339/qmj.2025.88
/content/journals/10.5339/qmj.2025.88
Loading

Data & Media loading...

  • Article Type: Review Article
Keyword(s): Guillain–Barré syndrome, IVIG, prognosis, second dose and treatment

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error